GlassScriptPhysician profile
Ashley Dunson
NPI 1932664398
$3,724.49
in general payments reported to CMS, 2019-2025
34 companies · $891 in 2025
The $891 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $589 · 2022: $500 · 2023: $895 · 2024: $849 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.43 | 2021-2025 | |
| Lilly USA, LLC | $422.57 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $371.74 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $364.71 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $176.94 | 2022-2025 | |
| Pfizer INC. | $163.18 | 2021-2025 | |
| Novo Nordisk INC | $138.25 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $133.06 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $132.70 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.72 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.69 | 2023-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $106.06 | 2022-2023 | |
| Amgen INC. | $82.21 | 2022-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $74.96 | 2022-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $63.74 | 2022-2025 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $63.05 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $56.27 | 2024-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $52.40 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $44.55 | 2025 | Hetlioz, Fanapt |
| Amarin Pharma, INC. | $37.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.49 | 2022 | |
| Radius Health, INC. | $27.88 | 2024 | Tymlos |
| Eisai INC. | $25.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.73 | 2024 | Xarelto |
| Inspire Medical Systems, INC. | $21.56 | 2025 | Inspire |
| Daiichi Sankyo INC. | $20.43 | 2023 | Injectafer |
| Corcept Therapeutics | $17.57 | 2023 | Korlym |
| Astellas Pharma US INC | $16.89 | 2023 | Veozah |
| Mylan Specialty L.P. | $16.44 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.60 | 2025 | Jornay Pm |
| Shield Therapeutics INC | $14.56 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.71 | 2023 | |
| Sunovion Pharmaceuticals INC. | $13.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Dunson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.